<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:b621c015c97047698083d0d63b3edcfa,x:a202d2e8bc264dad8eeef98c3e782f93-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:biib="http://www.biogenidec.com/20190929" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2019Q3" name="dei:AmendmentFlag" id="Fact-03824A059F7455F5BBD31EAA52CF9C9F-wk-Fact-03824A059F7455F5BBD31EAA52CF9C9F" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q3" name="dei:EntityCentralIndexKey" id="Fact-DF482AF5DB1C5A509DA314FBC5DF3702-wk-Fact-DF482AF5DB1C5A509DA314FBC5DF3702">0000875045</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="biib-20190929.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-09-29</xbrli:startDate>
			<xbrli:endDate>2019-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="s79F3A8546A2C5C5EB2B7DF83BC4E0411"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d25790482e68-wk-Fact-88379E6CB8B35AC6AE110BC9F78AD998" name="dei:DocumentType" contextRef="D2019Q3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">8-K</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Date of Report (Date of earliest event reported):  </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d25790482e86-wk-Fact-9F294FB3F96B5B528CB609235F68FF44" name="dei:DocumentPeriodEndDate" contextRef="D2019Q3" format="ixt:datemonthdayyearen">September 29, 2019</ix:nonNumeric></span></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:center;"><img src="biogenlogostandardrgbr.jpg" alt="biogenlogostandardrgbr.jpg" style="height:34px;width:102px;"></img></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d25790482e94-wk-Fact-52F09EEBD0695955A7A8FA500E629256" name="dei:EntityRegistrantName" contextRef="D2019Q3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">Biogen Inc.</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:16pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter) </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:38%;"></td><td style="width:31%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d25790482e116-wk-Fact-5D49C0C7F2B75BCDAE2FAB4912548233" name="dei:EntityIncorporationStateCountryCode" contextRef="D2019Q3" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d25790482e121-wk-Fact-D84E6FBA7E3E51E6BB345EA0E4096CCA" name="dei:EntityFileNumber" contextRef="D2019Q3">0-19311</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d25790482e126-wk-Fact-AD619A3C52D6520AB06F7193F58CDB0E" name="dei:EntityTaxIdentificationNumber" contextRef="D2019Q3">33-0112644</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(State or other jurisdiction of incorporation)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(Commission File Number)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(IRS Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d25790482e147-wk-Fact-EA89AB6840005930A8D8ABBAEF0B1767" name="dei:EntityAddressAddressLine1" contextRef="D2019Q3"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">225 Binney Street</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d25790482e152-wk-Fact-7C96FEFFE4BF58D9A7320FE2EB881EBB" name="dei:EntityAddressCityOrTown" contextRef="D2019Q3"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">Cambridge</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d25790482e157-wk-Fact-DA16276B028C5117AAC3DB9D19154AE7" name="dei:EntityAddressStateOrProvince" contextRef="D2019Q3" format="ixt-sec:stateprovnameen"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">Massachusetts</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d25790482e162-wk-Fact-E7AA54187BCA5523AB6D22B8F0316CF7" name="dei:EntityAddressPostalZipCode" contextRef="D2019Q3"><span style="font-family:Franklin Gothic Book,sans-serif;">02142</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(Address of principal executive offices; Zip Code)</span></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Registrant&#8217;s telephone number, including area code:  </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d25790482e178-wk-Fact-657E04DBB83D51DB81FCB136A01C5D38" name="dei:CityAreaCode" contextRef="D2019Q3"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d25790482e183-wk-Fact-AE5114F765625B27BA03266E8AF14083" name="dei:LocalPhoneNumber" contextRef="D2019Q3"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">679-2000</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Not Applicable</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(Former name or former address, if changed since last report.)</span></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span><ix:nonNumeric id="d25790482e204-wk-Fact-F8241E6AD0F55975921A43EE7E0B5135" name="dei:WrittenCommunications" contextRef="D2019Q3" format="ixt-sec:boolballotbox"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span><ix:nonNumeric id="d25790482e210-wk-Fact-6759C9F36C5553C9A9FA282E0B135005" name="dei:SolicitingMaterial" contextRef="D2019Q3" format="ixt-sec:boolballotbox"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span><ix:nonNumeric id="d25790482e216-wk-Fact-86AF0A48F9CB5B238BDF902767235459" name="dei:PreCommencementTenderOffer" contextRef="D2019Q3" format="ixt-sec:boolballotbox"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="line-height:120%;font-size:12pt;"><span><ix:nonNumeric id="d25790482e222-wk-Fact-46441A66B1CD598194859AFE97102C45" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2019Q3" format="ixt-sec:boolballotbox"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d25790482e274-wk-Fact-5916DBF42E03503E9AB3E919EB45B88E" name="dei:Security12bTitle" contextRef="D2019Q3">Common Stock, $0.0005 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d25790482e284-wk-Fact-9E37D39D98B65DA2B9158874E3D89683" name="dei:TradingSymbol" contextRef="D2019Q3">BIIB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d25790482e294-wk-Fact-26AFA13769595394A8DB24DD3A4E5CDB" name="dei:SecurityExchangeName" contextRef="D2019Q3" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span><ix:nonNumeric id="d25790482e305-wk-Fact-C8022F72D18D5BB5B2ED6E22199B2D8B" name="dei:EntityEmergingGrowthCompany" contextRef="D2019Q3" format="ixt-sec:boolballotbox"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Emerging growth company  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#9744;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;5.02 </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;On September 29, 2019, Michael D. Ehlers, M.D., Ph.D., notified Biogen Inc. (the &#8220;Company&#8221;) that he will step down as the Company&#8217;s Executive Vice President, Research and Development.  Alfred Sandrock, Jr., M.D., Ph.D., Executive Vice President, Chief Medical Officer, has been appointed  as Executive Vice President, Research and Development of the Company, effective immediately.</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7.01</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Regulation FD Disclosure.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 1, 2019, the Company issued a press release being furnished as Exhibit 99.1 and incorporated herein by reference.  The press release being furnished in this Item 7.01 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;8.01</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Other Events.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Company announced that Alphonse Galdes, Ph.D., has been appointed as the Company&#8217;s Executive Vice President, Pharmaceutical Operations and Technology.  </span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9.01 </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Financial Statements and Exhibits.</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibit listed below is furnished as part of this Current Report on Form 8-K.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:66%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibit 99.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pressreleaseoctober12019.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Press Release of Biogen Inc. issued October 1, 2019</span></a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">BIOGEN INC.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By: </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">     </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/Suzanne Murray</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">                                            </span></div><div style="line-height:120%;text-indent:372px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Suzanne Murray</span></div><div style="line-height:120%;text-indent:372px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporation Counsel and Assistant Secretary</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:  October 1, 2019</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "october120198-k.htm", "description": "8-K", "secsgml_size_bytes": 40478}]
{"company-data": {"conformed-name": "BIOGEN INC.", "cik": "0000875045", "assigned-sic": "2836", "irs-number": "330112644", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19311", "film-number": "191127580"}, "business-address": {"street1": "225 BINNEY STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02142", "phone": "7814642000"}, "mail-address": {"street1": "225 BINNEY STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02142"}, "former-company": [{"former-conformed-name": "BIOGEN IDEC INC.", "date-changed": "20070427"}, {"former-conformed-name": "BIOGEN IDEC INC", "date-changed": "20031112"}, {"former-conformed-name": "IDEC PHARMACEUTICALS CORP / DE", "date-changed": "19970530"}]}
Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 29, 2019
Biogen Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-19311
33-0112644
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
225 Binney Street
,
Cambridge
,
Massachusetts
02142
(Address of principal executive offices; Zip Code)
Registrant's telephone number, including area code:
(
617
)
679-2000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0005 par value
BIIB
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☐
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)    On September 29, 2019, Michael D. Ehlers, M.D., Ph.D., notified Biogen Inc. (the "Company") that he will step down as the Company's Executive Vice President, Research and Development.  Alfred Sandrock, Jr., M.D., Ph.D., Executive Vice President, Chief Medical Officer, has been appointed  as Executive Vice President, Research and Development of the Company, effective immediately.
Item 7.01
Regulation FD Disclosure.
On October 1, 2019, the Company issued a press release being furnished as Exhibit 99.1 and incorporated herein by reference.  The press release being furnished in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 8.01
Other Events.
The Company announced that Alphonse Galdes, Ph.D., has been appointed as the Company's Executive Vice President, Pharmaceutical Operations and Technology.
Item 9.01
Financial Statements and Exhibits.
The exhibit listed below is furnished as part of this Current Report on Form 8-K.
Exhibit No.
Description
Exhibit 99.1
Press Release of Biogen Inc. issued October 1, 2019
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOGEN INC.
By:
/s/Suzanne Murray
Suzanne Murray
Corporation Counsel and Assistant Secretary
Date:  October 1, 2019